Combating carbapenem-resistant Acinetobacter baumannii by an optimized imipenem plus tobramycin dosage regimen - prospective validation via hollow fiber infection and mathematical modeling [PublishAheadOfPrint]

We aimed to prospectively validate an optimized combination dosage regimen against a clinical carbapenem-resistant Acinetobacter baumannii (CRAB; MIC_Imipenem: 32mg/liter, MIC_Tobramycin: 2mg/liter). Imipenem at constant concentrations (7.6, 13.4 and 23.3mg/liter, reflecting a range of clearances) was simulated in a 7-day hollow fiber infection model (inoculum ~10^7.2 CFU/mL) with and without tobramycin (7mg/kg q24h, 0.5h infusions). While monotherapies achieved no killing or failed by 24h, this rationally optimized combination achieved >5 log₁₀ bacterial killing and suppressed resistance.

http://ift.tt/2mMayF9